Barclays
ACTU

Barclays’s Actuate Therapeutics ACTU Stock Holding History

Barclays’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645 Sell
421
-1,755
-81% -$4.07K ﹤0.01% 4973
2026
Q1 		$5.96K Sell
2,176
-12,770
-85% -$52.9K ﹤0.01% 4750
2025
Q4 		$91.5K Buy
14,946
+6,081
+69% +$41.8K ﹤0.01% 4608
2025
Q3 		$59.3K Sell
8,865
-28,469
-76% -$206K ﹤0.01% 4732
2025
Q2 		$228K Buy
+37,334
New +$326K ﹤0.01% 4194

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Barclays's ACTU Position: Q2 2026 in Review

Barclays reduced its Actuate Therapeutics (ACTU) stake by 81% in Q2 2026, selling an estimated $4.07K and leaving 421 shares worth $645. The position accounts for ﹤0.01% of the portfolio, ranked #4973.

Barclays first reported a position in ACTU in Q2 2025 and has held it in 5 quarters since. The position peaked at $228K in Q2 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Barclays held 421 shares of Actuate Therapeutics worth $645 as of Q2 2026.
  • Barclays sold 1,755 Actuate Therapeutics shares in Q2 2026, an estimated $4.07K.
  • Actuate Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4973 holding.
  • Barclays first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Actuate Therapeutics position peaked at $228K in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.